Predictors of the failure of treatment with pyrimethamine-sulfadoxine in children with uncomplicated falciparum malaria

Acta Tropica

Volumn 98, Issue 1, 2006, Pages 6-14

  Sowunmi, A ^a   Fateye, B A ^a   Adedeji, A A ^a   Gbotosho, G O ^a   Happi, T C ^a   Bamgboye, A E ^a   Bolaji, O M ^a   Oduola, A M J ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Children; Nigeria; Pyrimethamine sulfadoxine; Treatment failure

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; CHLORPHENIRAMINE; COTRIMOXAZOLE; FANSIDAR; PROBENECID;

ANTIMALARIAL AGENT; DISEASE PREVALENCE; DISEASE TREATMENT; DRUG RESISTANCE; HEALTH RISK; MALARIA;

ACUTE DISEASE; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; EVALUATION; FEMALE; FEVER; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTIVARIATE ANALYSIS; NIGERIA; PARASITE CONTROL; PLASMODIUM FALCIPARUM; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY;

AGING; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; NIGERIA; PREDICTIVE VALUE OF TESTS; PYRIMETHAMINE; RISK FACTORS; SULFADOXINE; TIME FACTORS; TREATMENT FAILURE;

AFRICA; NIGERIA; SUB-SAHARAN AFRICA; WEST AFRICA;

PLASMODIUM FALCIPARUM;

EID: 33646177533     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2005.11.009     Document Type: Article

References (43)

1. Anon. Epi Info Version 6. A Word Processing Data Base and Statistics Program for Public Health on IBM-compatible Microcomputers (1994), Centers for Disease Control and Prevention, Atlanta, GA
2. Dorsey G., Kamya M.R., Ndeezi G., Barbiye J.N., Phares C.R., Olson J.E., Katabira E.T., and Rosenthal P.J. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Am. J. Trop. Med. Hyg. 62 (2000) 686-692
3. Dorsey G., Vlahos J., Kamya M.R., Staedke S.G., and Rosenthal P.J. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J. Infect. Dis. 188 (2003) 1231-1238
4. Dorsey G., Gasasira A.F., Machekano R., Kamya M.R., Staedke S.G., and Hubbard A. The impact of age, temperature and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. Am. J. Trop. Med. Hyg. 71 (2004) 531-536
5. Ezeilo G.C. Neutropenia in Africans. Trop. Geog. Med. 23 (1971) 264-267
6. Federal Ministry of Health. National Antimalarial Treatment Policy (2004), Federal Ministry of Health, Abuja, Nigeria
7. Fehintola F.A., Adedeji A.A., Tambo E., Fateye B., Happi T.C., and Sowunmi A. Cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children: a clinical trial. Clin. Drug Invest. 24 (2004) 149-155
8. Fontanet A.L., and Walker A.M. Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand. Am. J. Trop. Med. Hyg. 49 (1993) 465-472
9. Hamer D.H., Macleod W.B., Addo-Yobo E., Duggan C.P., Estrella B., Fawzi W.W., Konde-Lule J.K., Mwanakasale V., Premji Z.G., Sempértegui F., Ssengooba F.P., Yeboah-Antwi K., and Simon J.L. Age, temperature, and parasitaemia predict chloroquine treatment failure and anaemia in children with uncomplicated Plasmodium falciparum malaria. Trans. R. Soc., Trop. Med. Hyg. 97 (2003) 422-428
10. Happi T.C., Thomas S.M., Gbotosho G.O., Falade C.O., Akinboye D.O., Gerena L., Hudson T., Sowunmi A., Kyle D.E., Milhous W., Wirth D.F., and Oduola A.M.J. Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from Nigeria. Ann. Trop. Med. Parasitol. 97 (2003) 439-451
11. Happi T.C., Gbotosho G.O., Sowunmi A., Falade C.O., Akinboye D.O., Gerena L., Kyle D.E., Milhous W., Wirth D.F., and Oduola A.M.J. Molecular analysis of Plasmodium falciparum recrudescent malaria infections in children treated with chloroquine in Nigeria. Am. J. Trop. Med. Hyg. 70 (2004) 20-26
12. Hess F.I., Iannuzzi A., Leafasia J., Cowdrey D., Nothdurft H.D., Von Sonnenburg F., Loscher T., and Rieckmann K.H. Risk factors of chloroquine resistance in Plasmodium falciparum malaria. Acta Trop. 61 (1996) 293-306
13. Ittarat W., Pickard A.L., Rattanasinganchan P., Wilairatana P., Looareesuwan S., Emery K., Low J., Udomsangpetch R., and Meshnick S.R. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factor. Am. J. Trop. Med. Hyg. 68 (2003) 147-152
14. Kyabayinze D., Cattamanchi A., Kamya M.R., Rosenthal P., and Dorsey G. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am. J. Trop. Med. Hyg. 69 (2003) 247-252
15. Méndez F., Muñoz A., Carrasquilla G., Jurado D., Arévalo-Herrera M., Cortese J.F., and Plowe C.V. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am. J. Epidemiol. 156 (2002) 230-238
16. Oduola A.M.J., Sowunmi A., Milhous W.K., Kyle D.E., Martin S.K., Walker O., and Salako L.A. Innate resistance to new antimalarial drug in Plasmodium falciparum from Nigeria. Trans. R. Soc., Trop. Med. Hyg. 86 (1992) 123-127
17. Price R., Nosten F., Simpson J.A., Luxemburger C., Phaipun L., Ter Kuile F., Van Vugt M., Chongsuphajaisiddhi T., and White N.J. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 60 (1999) 1019-1023
18. Salako L.A., Ajayi F.O., Sowunmi A., and Walker O. Malaria in Nigeria: a revisit. Ann. Trop. Med. Parasitol. 84 (1990) 435-445
19. Shaper A.G., and Lewis P. Genetic neutropenia in people of African origin. Lancet ii (1971) 1021-1023
20. Sibley C.H., Hyde J.E., Sims P.F.G., Plowe C.V., Kublin J.G., Mberu E.K., Cowman A.F., Winstanley P.A., Watkins W.M., and Alexis M.N. Pyrimethamine-sulphadoxine resistance in Plasmodium falciparum: what next?. Trends Parasitol. 17 (2001) 582-588
21. Sowunmi A., Oduola A.M.J., Ogundahunsi O.A.T., Falade C.O., Gbotosho G.O., and Salako L.A. Enhanced efficacy of chloroquine-chlorpheniramine combination in acute uncomplicated falciparum malaria in children. Trans. R. Soc., Trop. Med. Hyg. 91 (1997) 63-67
22. Sowunmi A., Oduola A.M.J., Ogundahunsi O.A.T., and Salako L.A. Comparative efficacy of chloroquine plus chlorpheniramine and pyrimethamine-sulfadoxine in acute uncomplicated falciparum malaria in Nigerian children. Trans. R. Soc., Trop. Med. Hyg. 92 (1998) 77-81
23. Sowunmi A. A randomized comparison of chloroquine and chloroqunie plus ketotifen, in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. Ann. Trop. Med. Parasitol. 97 (2003) 103-117
24. Sowunmi A., and Fateye B.A. Gametocyte sex ratio in children with asymptomatic, recrudescent, pyrimethamine-sulfadoxine-resistant Plasmodium falciparum malaria. Ann. Trop. Med. Parasitol. 97 (2003) 671-682
25. Sowunmi A., Fehintola F.A., Adedeji A.A., Gbotosho G.O., Falade C.O., Tambo E., Fateye B.A., Happi T.C., and Oduola A.M.J. Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Trop. Med. Int. Health 9 (2004) 606-614
26. Sowunmi A., Fateye B.A., Adedeji A.A., and Babalola C.P. Plasmodium falciparum hyperparasitaemia in children: risk factors, treatment outcomes, and gametocytaemia following treatment. Parasite 11 (2004) 317-323
27. Sowunmi A., Fateye B.A., Adedeji A.A., Fehintola F.A., and Happi T.C. Risk factor for gametocyte carriage in uncomplicated falciparum malaria in children. Parasitology 129 (2004) 255-262
28. Sowunmi A., Fateye B.A., Adedeji A.A., Fehintola F.A., Gbotosho G.O., Happi T.C., Tambo E., and Oduola A.M.J. Predictors of the failure of treatment with chloroquine in children with acute, uncomplicated, Plasmodium falciparum malaria in an area with high and increasing chloroquine resistance. Ann. Trop. Med. Parasitol. 99 (2005) 535-544
29. SPSS. SPSS for Windows Release 10.01 (Standard Version) (1999), SPSS Inc., Chicago, IL, USA
30. Staedke S.G., Sendagire H., Lamola S., Kamya M.R., Dorsey G., and Rosenthal P. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health 9 (2004) 624-629
31. Talisuna A.O., Bloland P., and D'alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin. Microbiol. Rev. 17 (2004) 235-254
32. Ter Kuile F.O., Luxemburger C., Nosten F., Thwai K.L., Chongsuphajasiddhi T., and White N.J. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans. R. Soc., Trop. Med. Hyg. 89 (1995) 660-664
33. Terlouw D.J., Courval J.M., Kolczac M.S., Rosenberg O.S., Oloo A.J., Kager P.A., Lal A.A., Nahlen B.L., and Ter Kuile F.O. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in western Kenya. J. Infect. Dis. 187 (2003) 467-476
34. Terlouw D.J., Nahlen B.L., Courval J.M., Kariuki S.K., Rosenberg O.S., Oloo A.J., Kolczac M.S., Hawley W.A., Lal A.A., and Ter Kuile F.O. Sulfadoxine-pyrimethamine in treatment of malaria in western Kenya: increasing resistance and underdosing. Antimicrob. Agents Chemother. 47 (2003) 2929-2932
35. Trape J.-F., Pison G., Preziosi M.-P., Enel C., Du Lou A.D., Delaunay V., Samb B., Lagarde E., Molez J.-F., and Simondon F. Impact of chloroqunine resistance on malaria mortality. Life Sci. 321 (1998) 689-697
36. Trape J.-.F. The public health impact of chloroquine resistance in Africa. Am. J. Trop. Med. Hyg. 64 Suppl. (2001) 12-17
37. Von Seidlein L., Drakeley C., Greenwood B., Walraven G., and Targett G. Risk factors for gametocyte carriage in Gambian children. Am. J. Trop. Med. Hyg. 65 (2001) 523-526
38. Wang P., Lee C.-S., Bayoumi R., Djimde A., Doumbo O., Swedberg G., Dao L.D., Mshinda H., Tanner M., Watkins W.M., Sims P.G.F., and Hyde J.E. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origin. Mol. Biochem. Parasitol. 89 (1997) 161-177
39. White N.J. Why is it that antimalarial drug treatments do not always work?. Ann. Trop. Med. Parasitol. 92 (1998) 449-458
40. World Health Organization, 1973. Chemotherapy of malaria and resistance to antimalarials. Technical Report Series No. 529. WHO, Geneva.
41. World Health Organization. Severe falciparum malaria. Trans. R. Soc., Trop. Med. Hyg. 94 Suppl. 1 (2000)
42. World Health Organization, 2001a. The use of antimalarial drugs. Report of a WHO informal consultation. Document WHO/CDS/RBM/2001.33. WHO, Geneva.
43. World Health Organization, 2001b. The use of antimalarial drugs. Report of a WHO informal consultation. Document WHO/CDS/RBM/2001.35. WHO, Geneva.